Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Dec;29(12):7461-7469.
doi: 10.1007/s00520-021-06321-7. Epub 2021 Jun 3.

Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis

Jialin Gu #  1   2 , Hong Lu #  3 , Chen Chen  2   4 , Zhancheng Gu  1   2 , Miao Hu  1   2 , Ling Liu  1   2 , Jialin Yu  1   5 , Guoli Wei  6   7 , Jiege Huo  8   9
Affiliations
Meta-Analysis

Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis

Jialin Gu et al. Support Care Cancer. 2021 Dec.

Abstract

Background: To identify the association between diabetes mellitus (DM) and the risk of chemotherapy-induced peripheral neuropathy (CIPN) through a systematic review and meta-analysis.

Methods: An electronic literature search was conducted in PubMed, Embase, Web of Science, the Wanfang database, the VIP Journals database (CQVIP), the China National Knowledge Infrastructure (CNKI) database, and the China Biology Medicine database (Sinomed) between January 2010 and January 2021. Articles were included if they investigated CIPN and DM. Stata 15.1 was used to analyze the data.

Results: We examined 8923 cancer patients from 25 studies comprising 9 cohort studies and 16 case-control studies. Meta-analysis showed that there was a statistically significant positive correlation between DM and CIPN (odds ratio [OR] = 1.60, 95% confidence interval [CI] = 1.38-1.85, P < 0.001). Egger's test (P = 0.824) showed no evidence of publication bias. The positive associations did not significant differ by study type, study quality, evaluation instrument, and type of antineoplastic drug. Omission of any single study had little effect on the combined risk estimate. Little evidence of heterogeneity was observed.

Conclusion: This meta-analysis provides evidence of a significant positive association between DM and risk of CIPN. Furthermore, a more detailed evaluation is warranted for cancer patients with diabetes when they are treated with antineoplastic drugs that have the potential to cause peripheral neuropathy.

Keywords: Chemotherapy-induced peripheral neuropathy (CIPN); Diabetes mellitus (DM); Meta-analysis; Risk.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
PRISMA flow chart of study identification and selection
Fig. 2
Fig. 2
Forest plot of the meta-analysis of the association between diabetes mellitus and chemotherapy-induced peripheral neuropathy
See this image and copyright information in PMC

References

    1. Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63:419–437. doi: 10.3322/caac.21204. - DOI - PubMed
    1. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44:1507–1515. doi: 10.1016/j.ejca.2008.04.018. - DOI - PubMed
    1. Boyette-Davis JA, Walters ET, Dougherty PM. Mechanisms involved in the development of chemotherapy-induced neuropathy. Pain Manag. 2015;5:285–296. doi: 10.2217/pmt.15.19. - DOI - PMC - PubMed
    1. Ewertz M, Qvortrup C, Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol. 2015;54:587–591. doi: 10.3109/0284186X.2014.995775. - DOI - PubMed
    1. Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, Lafky JM, Wagner-Johnston ND, Ruddy KJ, Dakhil S, Staff NP, Grothey A, Loprinzi CL. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance) J Clin Oncol. 2015;33(30):3416–3422. doi: 10.1200/JCO.2014.58.8533. - DOI - PMC - PubMed

MeSH terms

Substances